Similar Items: Feasibility of a 50% Dosing Interval Extension of Anti–IL-5 Biologics in Patients with Severe Asthma in Clinical Remission: A Real-World Validation Study
- Clinical Remission in Severe T2‐High Asthma in Real Life After Anti‐IgE, Anti‐IL‐5 and Anti‐IL5R: A Potential Role for CRP as a Biomarker
- Clinical Remission in Patients with Severe Eosinophilic Asthma – A Single-Arm Observational Study with Benralizumab
- Biologic Underutilization and Healthcare Burden in US Patients with Type 2 Severe Asthma
- Assessment of Inhaled Corticosteroid Adherence in Adults with Severe Asthma Receiving Biologic Therapy: A Retrospective Observational Study
- Adherence to Biologic Therapies is Associated with Improved Clinical Outcomes and Reduced Healthcare Resource Utilization in Patients with Severe Asthma in Japan
- Benralizumab Reduces Asthma Exacerbations and Costs Among Medicare Beneficiaries with Severe Asthma: The ZEPHYR-5 Study